Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
-
The lack of benefit in terms of overall survival for
2023-02-10
The lack of benefit in terms of overall survival for antiangiogenic treatment was similar when antiangiogenic drug was used both as first and second-line therapy, and both in association with cytotoxic treatment or alone. Noteworthy, a trend for an inferior outcome was observed in the group of patie
-
Volasertib Dual acting RAAS blockade and neprilysin inhibiti
2023-02-10
Dual-acting RAAS blockade and neprilysin inhibition has been evaluated in several clinical HF trials. In PARADIGM-HF [6,7], LCZ696 was superior to enalapril in reducing mortality and HF hospitalizations in symptomatic patients with HF with reduced EF. Augmented benefits on maladaptive cardiac remode
-
br Introduction Heart Failure HF is a major
2023-02-10
Introduction Heart Failure (HF) is a major and growing health challenge in India and the developing countries. It is one of the most important causes of morbidity and mortality in the industrialized world. The incidence and prevalence estimates of HF are unreliable in India because of the lack of
-
br Concluding Remarks and Future Perspectives While postmort
2023-02-09
Concluding Remarks and Future Perspectives While postmortem human Rivaroxaban material is relatively sparse and has inherent limitations as discussed above, additional investigations could benefit from analysis of in vitro cellular models to corroborate findings in patient material. Generation o
-
In the past years the
2023-02-08
In the past 10 years, the role of the CD73-adenosinergic pathway in suppression of anti-tumor immunity has increasingly been recognized [13], [14]. In this review, we discuss the latest findings dealing with the regulation of anti-tumor immunity by CD73 and adenosine. We also discuss ongoing clinica
-
br Discussion One binding site MB Fig is located
2023-02-08
Discussion One binding site, MB327-1 (Fig. 4) is located in the extracellular domain between the γ and α subunits. MB327 adopts an extended conformation in the MB327-1 site and is oriented parallel to the channel. The second putative binding site, MB327-2 (Fig. 4) is situated deep inside the chan
-
Aurora A or B selective and pan aurora inhibitors have
2023-02-08
Aurora -A or -B selective and pan-aurora inhibitors have demonstrated different preclinical and clinical therapeutic efficacies [2,[19], [20], [21], [22], [23]]. For example, clinical trials for a pan-Aurora inhibitor VX-680 (developed by Vertex) were halted at phase II for toxicity reasons (one cas
-
Previous investigations have established that aromatase acti
2023-02-08
Previous investigations have established that aromatase activity is regulated via two different pathways in a tissue-specific manner. The first is a slower transcription regulatory pathway that involves an alteration in gene transcription and represents what is classically thought of as the way by w
-
The neural circuitry involved in the production of the EOD
2023-02-08
The neural circuitry involved in the production of the EOD, its modulations, and in the sensory processing of communication signals has been well characterized (Bell and Maler, 2005; Chacron et al., 2011; Krahe and Maler, 2014; reviewed in Metzner, 1999). Pacemaker cells located in the pacemaker nuc
-
TPEN In summary this report demonstrates another successful
2023-02-08
In summary, this report demonstrates another successful application of gene editing in iPSCs. Despite the lack of efficient metabolic functional repair after transplantation, the application of gene correction into HLCs might still be a realistic goal for ex vivo gene therapy of liver diseases with
-
8380 synthesis Although apelin g kg shows negative early
2023-02-08
Although apelin 60μg/kg shows negative (early) and positive (late) inotropic effects, since ERK1/2 phosphorylation starts at the min 5 of administration [6], ERK1/2 phosphorylation mediate positive inotropic effects of apelin 60μg/kg. After the simultaneous inhibition of KOR and APJ the phosphoryla
-
Available data thus indicate that there are
2023-02-08
Available data thus indicate that there are at least two ways that HMGA proteins can induce localized changes in the chromatin structure of inducible gene promoters, both of which involve positioned nucleosomes that must be “remodeled” before gene transcription can occur. The first mechanism is exem
-
Finally we argue that the estimated penetrance
2023-02-08
Finally, we argue that the estimated penetrance of 0.45% (95% CI 0.02%, 9.35%) calculated by leveraging the gnomAD (Lek et al., 2016) population data indicate that T201S is at most a low-risk gene variant for CJD. If we arbitrarily consider a central estimate of 10% or higher as the clinically signi
-
To date attention has been directed towards new molecular
2023-02-08
To date, attention has been directed towards new molecular targets in luminal phenotype (ER-positive), such as CDK4/6 and, to a lesser extent, androgen receptor (AR) pathways [8]. While the role of CDK4/6 has been elucidated and their inhibitors have shown a benefit in luminal BC, the role of AR in
-
891 We have recently begun to demonstrate
2023-02-08
We have recently begun to demonstrate this concept by reporting a novel class of β-hairpin peptidomimetics, built on a piperidine-pyrrolidine semi-rigid β-turn inducer [12] and bearing two recognition pentapeptide sequences, designed on oligomeric and fibril structures of Aβ1-42 (compound 1, Fig. 1)
15493 records 296/1033 page Previous Next First page 上5页 296297298299300 下5页 Last page